Update on lipids and C-reactive protein in acute and chronic coronary heart disease.
作者信息
Jones Peter H
机构信息
Baylor College of Medicine, Methodist DeBakey Heart & Vascular Center, Houston, Texas 77030, USA.
出版信息
Tex Heart Inst J. 2010;37(3):307-8.
Abstract
摘要
相似文献
1
Update on lipids and C-reactive protein in acute and chronic coronary heart disease.
Tex Heart Inst J. 2010;37(3):307-8.
2
The role of lipid-lowering therapy in preventing coronary heart disease in patients with type 2 diabetes.
Clin Cardiol. 2008 Jun;31(6):241-8. doi: 10.1002/clc.20226.
3
What works and in whom? A simple, easily applied, evidence-based approach to guidelines for statin therapy.
Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):592-3. doi: 10.1161/CIRCOUTCOMES.112.966556.
4
Do lipids and apolipoproteins predict coronary heart disease under statin and fibrate therapy in the primary prevention setting in community-dwelling elderly subjects? The 3C Study.
Atherosclerosis. 2011 Feb;214(2):426-31. doi: 10.1016/j.atherosclerosis.2010.10.040. Epub 2010 Nov 3.
5
Lipids: new guidelines, intensive treatment, and future directions.
Tex Heart Inst J. 2006;33(2):180-3.
6
7
Managing the dyslipidemia of metabolic syndrome: beyond statin therapy.
Metab Syndr Relat Disord. 2012 Jun;10(3):159-60. doi: 10.1089/met.2012.1500. Epub 2012 May 8.
8
Trust the Blinded Randomized Evidence That Statin Therapy Rarely Causes Symptomatic Side Effects.
Circulation. 2018 Oct 9;138(15):1499-1501. doi: 10.1161/CIRCULATIONAHA.118.036846.
9
[On behalf and the extent of evidence].
Rev Med Suisse. 2010 Jun 9;6(252):1171-2.
10
Should we measure C-reactive protein levels to ascertain the adequacy of statin therapy in patients who are at very high risk for a coronary heart disease event?
Am Heart J. 2005 Oct;150(4):650-1. doi: 10.1016/j.ahj.2005.08.001.
本文引用的文献
1
Effects of combination lipid therapy in type 2 diabetes mellitus.
N Engl J Med. 2010 Apr 29;362(17):1563-74. doi: 10.1056/NEJMoa1001282. Epub 2010 Mar 14.
2
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.
Lancet. 2010 Jan 9;375(9709):132-40. doi: 10.1016/S0140-6736(09)61717-7. Epub 2009 Dec 22.
3
Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction.
J Am Coll Cardiol. 2009 Dec 1;54(23):2157-63. doi: 10.1016/j.jacc.2009.07.005. Epub 2009 Aug 6.
4
Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial.
J Am Coll Cardiol. 2009 Aug 4;54(6):558-65. doi: 10.1016/j.jacc.2009.05.028. Epub 2009 Jul 2.
5
Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease.
JAMA. 2009 Jul 1;302(1):37-48. doi: 10.1001/jama.2009.954.
6
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.
7
Genetically elevated C-reactive protein and ischemic vascular disease.
N Engl J Med. 2008 Oct 30;359(18):1897-908. doi: 10.1056/NEJMoa0707402.
8
Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation.
Diabetes Care. 2008 Apr;31(4):811-22. doi: 10.2337/dc08-9018.
Zotero 插件